The clock is ticking on ENTA’s decision whether to opt in for US profit sharing on the ABT-493/ABT-530 regimen. I don’t know the exact decision deadline, but it has to be soon insofar as the phase-2b study has begun (#msg-106122063).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.